Results 51 to 60 of about 22,142 (188)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation.
Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose   +6 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance

Journal of Advanced Research
Introduction: Patients with mantle cell lymphoma (MCL) frequently develop resistance to ibrutinib. Lymphoma-associated macrophages (LAMs) may play a causal role in this resistance but remain underexplored in current literature.
Xiaoqing Sun, Caiqin Wang, Jianghua Cao, Jing Li, Gang Ma, Xianqiu Wu, Peng Sun, Yu Wang, Jiajia Huang, Robert Peter Gale, Zhiming Li   +10 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Dual Mechanism of Severe Bleeding Diathesis in a Patient with CLL: Acquired Von Willebrand Syndrome and Ibrutinib - Mediated Platelets Dysfunction [PDF]

, 2020
We here report an informative case of severe bleeding diathesis in a patient with Chronic Lymphocytic Leukaemia (CLL), due to Acquired Von Willebrand Syndrome (AVWS) and impaired platelets aggregation under the treatment with Ibrutinib. Keywords:
Novak, U, Bürki, S
core   +1 more source

Trends and Future Directions in Organic Chemistry for Drug Discovery

Chemistry – A European Journal, EarlyView.
Organic synthesis is being reshaped by the convergence of catalytic innovation, automation, artificial intelligence, and emerging therapeutic modalities. Late‐stage functionalization, photoredox and electrochemical methods, biocatalysis, flow chemistry, DELs, and proximity‐based drugs are examined as components of closed‐loop discovery.
Paweł Kozyra, Maciej Masłyk
wiley   +1 more source

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Ibrutinib: a paradigm shift in management of CLL [PDF]

, 2014
B-cell receptor (BCR) signaling plays a vital role in B-cell malignancies; Bruton tyrosine kinase is a critical mediator of this signaling. BCR signaling, either constitutively or following antigen binding, leads to activation of several downstream ...
Burger, Jan A, O’Brien, Susan, Wierda, William G, Badar, Talha   +3 more
core   +1 more source

Association between ibrutinib treatment and hypertension

, 2021
BACKGROUND: Ibrutinib is a tyrosine kinase inhibitor most commonly associated with atrial fibrillation. However, additional cardiotoxicities have been identified, including accelerated hypertension.
Viganego, Federico, Hawk, Fahad, Chavez, Juliio C, Pinilla-Ibarz, Javier, Fradley, Michael, Schabath, Matthew B, Lee, Dae Hyun, Emole, Josephine, Gliksman, Matthew, Welter-Frost, Allan, Seok, Kieun, Rhea, Isaac B, Armanious, Merna, Shah, Bijal   +13 more
core   +1 more source